Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
Lupin will provide five lakh LupiSafe hand sanitizers to policemen and frontline workers deployed at strategic locations
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Subscribe To Our Newsletter & Stay Updated
